Bicycle Therapeutics plc (FRA:50BA)

Bicycle Therapeutics Statistics

Total Valuation

FRA:50BA has a market cap or net worth of EUR 257.80 million. The enterprise value is -209.50 million.

Market Cap	257.80M
Enterprise Value	-209.50M

Important Dates

The next estimated earnings date is Monday, August 3, 2026.

Earnings Date	Aug 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+6.99%
Shares Change (QoQ)	+0.46%
Owned by Insiders (%)	1.80%
Owned by Institutions (%)	39.29%
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.68
PB Ratio	0.54
P/TBV Ratio	0.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	1.10
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	1.04

Financial Position

The company has a current ratio of 12.66, with a Debt / Equity ratio of 0.03.

Current Ratio	12.66
Quick Ratio	12.28
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.07
Interest Coverage	-1,173.12

Financial Efficiency

Return on equity (ROE) is -33.84% and return on invested capital (ROIC) is -22.58%.

Return on Equity (ROE)	-33.84%
Return on Assets (ROA)	-19.38%
Return on Invested Capital (ROIC)	-22.58%
Return on Capital Employed (ROCE)	-39.46%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	191,216
Profits Per Employee	-659,603
Employee Count	288
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:50BA has paid 1.22 million in taxes.

Income Tax	1.22M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -48.92% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-48.92%
50-Day Moving Average	3.97
200-Day Moving Average	5.22
Relative Strength Index (RSI)	44.31
Average Volume (20 Days)	35

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.32

Income Statement

In the last 12 months, FRA:50BA had revenue of EUR 55.07 million and -189.97 million in losses. Loss per share was -2.74.

Revenue	55.07M
Gross Profit	-134.67M
Operating Income	-206.54M
Pretax Income	-188.74M
Net Income	-189.97M
EBITDA	-201.41M
EBIT	-206.54M
Loss Per Share	-2.74

Balance Sheet

The company has 485.23 million in cash and 13.30 million in debt, with a net cash position of 471.93 million.

Cash & Cash Equivalents	485.23M
Total Debt	13.30M
Net Cash	471.93M
Net Cash Per Share	n/a
Equity (Book Value)	480.76M
Book Value Per Share	6.90
Working Capital	494.57M

Cash Flow

In the last 12 months, operating cash flow was -198.81 million and capital expenditures -2.13 million, giving a free cash flow of -200.94 million.

Operating Cash Flow	-198.81M
Capital Expenditures	-2.13M
Depreciation & Amortization	5.10M
Net Borrowing	-164,646
Free Cash Flow	-200.94M
FCF Per Share	n/a

Margins

Gross Margin	-244.54%
Operating Margin	-375.05%
Pretax Margin	-342.73%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:50BA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.99%
Shareholder Yield	-6.99%
Earnings Yield	-73.69%
FCF Yield	-77.95%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:50BA has an Altman Z-Score of 0.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.92
Piotroski F-Score	2